Objectives. Identify risk factors for at-term small for gestational age newborns. Materials and methods. Retrospective cohort study using data from the Maternal Perinatal Information System of the Maria Auxiliadora Hospital of Lima, from the period 2000-2010. Maternal age, parity, education level, marital status, pregestational body mass index, number of prenatal care visits, presence of conditions such as preeclampsia, eclampsia, urinary tract infection and gestational diabetes as risk factors in small for gestational age newborns were evaluated. The weight for gestational age was calculated based on Peruvian percentiles. Crude relative risk (RR) and adjusted (ARR) were calculated with confidence intervals of 95% using log-binomial generalized linear models. Results. 64,670 pregnant women were included. The incidence for small for gestational age was 7.2%. Preeclampsia (ARR 2.0, 95% CI: 1.86 to 2.15), eclampsia (ARR 3.22, 95% CI: 2.38 to 4.35), low maternal weight (ARR 1.38; 95% CI: 1.23 to 1.54), nulliparity (ARR 1.32, 95% CI: 1.23 to 1.42), age ≥35 years (ARR 1.16, 95% CI: 1.04 -1.29), having prenatal care visits from 0 to 2 (ARR 1.43, 95% CI: 1.32 to 1.55) and 3 to 5 (ARR 1.22, 95% CI: 1.14 to 1.32) were risk factors for small for gestational age. Conclusions. It is necessary to identify pregnant women with risk factors such as those found to decrease the condition of small for gestational age. Actions should emphasize modifiable factors, such as the frequency of prenatal care visits.
Author(s): Tejeda Mariaca, J. Eduardo; Pizango Mallqui, Orion; Alburquerque Duglio, Miguel; Mayta Tristán, Percy
Source: Revista Peruana de Medicina Experimental y Salud Pública (Rev Peru Med Exp Salud Publica)
URL: http://hdl.handle.net/10757/582632
Producción académica de de la Universidad Peruana de Ciencias Aplicadas - UPC
miércoles, 25 de noviembre de 2015
Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru
Objective
To evaluate the cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine (PCV10) versus the 13-valent PCV (PCV13) to the National Immunization Schedule in Peru for prevention of pneumococcal disease (PD) in children <5 years of age.
Methods
The integrated TRIVAC vaccine cost-effectiveness model from the Pan American Health Organization's ProVac Initiative (version 2.0) was applied from the perspective of the Government of Peru. Twenty successive cohorts of children from birth to 5 years were evaluated. Clinical outcomes were pneumococcal pneumonia (PP), pneumococcal meningitis (PM), pneumococcal sepsis (PS) and acute otitis media from any causes (AOM). Measures included prevention of cases, neurological sequelae (NS), auditory sequelae (AS), deaths and disability adjusted life years (DALYs). A sensitivity analyses was also performed.
Findings
For the 20 cohorts, net costs with PCV10 and PCV13 were US$ 363.26 million and US$ 408.26 million, respectively. PCV10 prevented 570,273 AOM; 79,937 PP; 2217 PM; 3049 PS; 282 NS; 173 AS; and 7512 deaths. PCV13 prevented 419,815 AOM; 112,331 PN; 3116 PM; 4285 PS; 404 NS; 248 AS; and 10,386 deaths. Avoided DALYs were 226,370 with PCV10 and 313,119 with PCV13. Saved treatment costs were US$ 37.39 million with PCV10 and US$ 47.22 million with PCV13. Costs per DALY averted were US$ 1605 for PCV10, and US$ 1304 for PCV13. Sensitivity analyses showed similar results. PCV13 has an extended dominance over PCV10.
Conclusion
Both pneumococcal vaccines are cost effective in the Peruvian context. Although the net cost of vaccination with PCV10 is lower, PCV13 prevented more deaths, pneumococcal complications and sequelae. Costs per each prevented DALY were lower with PCV13. Thus, PCV13 would be the preferred policy; PCV10 would also be reasonable (and cost-saving relative to the status quo) if for some reason 13-valent were not feasible.; This study was presented at 9th International Symposium of
Pneumococci and Pneumococcal Diseases, Hyderabad, India, March
2014, and supported by the National Council of Science, Technology
and Technological Innovation of Peru (CONCYTEC) and
International Clinical Epidemiology Network (INCLEN Trust).
Author(s): Mezones Holguin, Edward; Canelo Aybara, Carlos; David Clark, Andrew; Bess Janusz, Cara; Jaúregui, Bárbara;Escobedo Palza, Seimer; Hernandez, Adrian V.; Berhane, Yemane; Vega Porras, Denhiking; González, Marco;Fiestas, Fabián; Toledo , Washington; Michele, Fabiana; Suárez, Víctor J.
Source: Vaccine
URL: http://hdl.handle.net/10757/582635
Author(s): Mezones Holguin, Edward; Canelo Aybara, Carlos; David Clark, Andrew; Bess Janusz, Cara; Jaúregui, Bárbara;Escobedo Palza, Seimer; Hernandez, Adrian V.; Berhane, Yemane; Vega Porras, Denhiking; González, Marco;Fiestas, Fabián; Toledo , Washington; Michele, Fabiana; Suárez, Víctor J.
Source: Vaccine
URL: http://hdl.handle.net/10757/582635
Insulin resistance and endometrial cancer risk: A systematic review and meta-analysis
Abstract Aim: It has been suggested that chronic hyperinsulinemia from insulin resistance is
involved in the etiology of endometrial cancer (EC). We performed a systematic review and
meta-analysis to assess whether insulin resistance is associated with the risk of EC.
Methods: We searched PubMed-Medline, Embase, Scopus, and Web of Science for articles
published from database inception through 30th September 2014. We included all observational
studies evaluating components defining insulin resistance in women with and without
EC. Quality of the included studies was assessed by NewcastleeOttawa scale. Randomeffects
models and inverse variance method were used to meta-analyze the association between
insulin resistance components and EC.
Results: Twenty-five studies satisfied our inclusion criteria. Fasting insulin levels (13 studies,
n Z 4088) were higher in women with EC (mean difference [MD] 33.94 pmol/L, 95% confi-
dence interval [CI] 15.04e52.85, p Z 0.0004). No differences were seen in postmenopausal
versus pre- and postmenopausal subgroup analysis. Similarly, non-fasting/fasting C-peptide
levels (five studies, n Z 1938) were also higher in women with EC (MD 0.14 nmol/L, 95% CI 0.08e0.21, p < 0.00001). Homeostatic model assessment - insulin resistance (HOMA-IR)
values (six studies, n Z 1859) in EC patients were significantly higher than in women without
EC (MD 1.13, 95% CI 0.20e2.06, p Z 0.02). There was moderate-to-high heterogeneity
among the included studies.
Conclusion: Currently available epidemiologic evidence is suggestive of significantly higher
risk of EC in women with high fasting insulin, non-fasting/fasting C-peptide and HOMAIR
values.
Author(s): Hernandez, Adrian V.; Pasupuleti, Vinay; Benites Zapata, Vicente A.; Thota, Priyaleela; Deshpande, Abhishek;Perez Lopez, Faustino R.
Source: European Journal of Cancer
URL: http://hdl.handle.net/10757/582697
Author(s): Hernandez, Adrian V.; Pasupuleti, Vinay; Benites Zapata, Vicente A.; Thota, Priyaleela; Deshpande, Abhishek;Perez Lopez, Faustino R.
Source: European Journal of Cancer
URL: http://hdl.handle.net/10757/582697
viernes, 20 de noviembre de 2015
Are medical students able to perform multicenter studies?
Are medical students able to perform multicenter studies?
This question goes far beyond what the scientific
environment could imagine even a few years ago.
Medical students, particularly in Latin America, have
progressively incremented their research
productivity[1],[2]. This is due to the strategies developed
—such as the creation of medical students’ scientific
societies— in response to the lack of a culture of research
and publishing in the continent [3],[4].
As these improvements have been rising, new research
challenging opportunities have emerged. Multicenter
studies are an example. We would like to relate the
experience of a project we ran in 85 universities of 17 Latin
American countries in which the main local researchers
were medical students, conforming then the Collaborative
Working Group for the Research of Human Resources for
Health (Red-LIRHUS) [5]. In order to do so, we will mention
the main advantages and complications in carrying out a
multicenter study with medical students as investigators.
Author(s): Pereyra Elías, Reneé; Montenegro Idrogo, Juan José; Mayta Tristán, Percy ( 0000-0002-0861-6606 )
Source: Medwave (Medwave)
URL: http://hdl.handle.net/10757/579916
Author(s): Pereyra Elías, Reneé; Montenegro Idrogo, Juan José; Mayta Tristán, Percy ( 0000-0002-0861-6606 )
Source: Medwave (Medwave)
URL: http://hdl.handle.net/10757/579916
Dispositivo intrauterino parcialmente migrado e incrustado en serosa de rectosigmoides tras 8 años de inserción
Se presenta el caso clínico de un dispositivo intrauterino parcialmente migrado a cavidad pélvica e incrustado
en serosa de rectosigmoides luego de 8 años de su inserción. El diagnóstico se realizó mediante
ecografía transvaginal y retiro del dispositivo por laparoscopia. Se realizó rafia de serosa rectal y de útero.
La paciente tuvo un postoperatorio sin complicaciones.
Autor(es): Bernuy P., Sandra; Rivera N., María Cristina; Salazar L., Carmen; Ramírez C., Fernando
Fuente: Revista Chilena de Obstetrica y Ginecología (Rev. Chil. Obstet. Ginecol.)
URL: http://hdl.handle.net/10757/582068
Autor(es): Bernuy P., Sandra; Rivera N., María Cristina; Salazar L., Carmen; Ramírez C., Fernando
Fuente: Revista Chilena de Obstetrica y Ginecología (Rev. Chil. Obstet. Ginecol.)
URL: http://hdl.handle.net/10757/582068
Suscribirse a:
Entradas (Atom)